Read more

June 19, 2020
1 min read
Save

FDA clears IND application for ’dual-switch’ CAR-T for HER2-positive tumors

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA cleared an investigational new drug application for BPX-603, a chimeric antigen receptor T-cell therapy for the treatment of HER2-positive solid tumors, according to a press release from the agent’s manufacturer.

BPX-603 (Bellicum Pharmaceuticals) is an autologous CAR T-cell therapy that uses Bellicum’s proprietary dual-switch GoCAR-T. The technology allows clinicians to either activate or eliminate the CAR T cells with the administration of small molecules to enhance real-time control of the agent.

Two light switches.
GoCAR-T technology allows clinicians to either activate or eliminate CAR T cells with the administration of small molecules to enhance real-time control of the agent.

BPX-603 targets tumors that express HER2. The approval allows Bellicum to move forward with a phase 1/phase 2 clinical trial to evaluate the safety and efficacy of BPX-603 for HER2-positive solid tumors.

Previous studies of CAR T-cell technology that targets HER2-postive tumors have shown some antitumor activity but have been limited by modest clinical efficacy and off-tumor/on-target toxicity, according to Bellicum.

“The FDA’s clearance of our IND for BPX-603 marks a significant milestone for Bellicum, adding a second clinical program to further evaluate our novel GoCAR-T technology’s ability to enhance CAR-T and host immune cell activity against solid tumors,” Rick Fair, president and CEO of Bellicum, said in the release. “We look forward to initiating our phase 1/2 trial with BPX-603 targeting solid tumors that express HER2 later this year.”

Bellicum is conducting a phase 1/phase 2 clinical trial of its GoCAR-T technology among patients with pancreatic, gastric or prostate cancers whose tumors express the prostate stem cell antigen.